• Endogenous Melatonin in LPS-Activated Macrophages

  2026-10-13

  A source-grounded overview of a 2024 Experimental Cell Research study examining how LPS-induced macrophage activation affects endogenous melatonin synthesis, and whether that melatonin feeds back on inflammatory polarization, oxidative stress and apoptosis.

• What the ISG20 Atherosclerosis Evidence Shows

  2026-10-12

  A 2025 study links CLEC5A and ISG20 with atherosclerosis using transcriptomic, eQTL and Mendelian-randomization analyses, with additional model-based validation for ISG20. The findings are biologically suggestive but do not establish a clinical treatment target or prove that altered ISG20 activity independently causes human plaque progression.

• Toremifene and the TSPAN18–STIM1 Evidence Gap

  2026-10-12

  The supplied prostate cancer study supports a TSPAN18–STIM1 mechanism in bone-metastasis models, but it does not test Toremifene. Supplier-reported Toremifene activity therefore cannot be used to establish effects on this pathway, therapeutic benefit, or clinical applicability.

• ORAI2 and Early Salivary Gland Fibrosis

  2026-10-11

  The cited study links ORAI2-mediated store-operated calcium entry to early postirradiation salivary-gland fibrosis through a proposed JNK/NFAT1/TGF-β1 pathway. Its multi-model findings are mechanistically coherent but remain preclinical, with important limits concerning pharmacologic specificity, duration, and clinical applicability.

• Boc-D-FMK: Reading Caspase Evidence

  2026-10-10

  Boc-D-FMK is a cell-permeable pan-caspase inhibitor used to test whether caspase activity contributes to apoptosis and inflammation. This article develops an evidence-centered framework linking its interpretation to the 2025 ATF5–CYP2B6 glioblastoma study without overstating mechanistic or translational conclusions.

• Antimycin A4: Evidence, Uses, and Limitations

  2026-10-09

  Antimycin A4 is presented by APExBIO as a mitochondrial respiratory-chain inhibitor and ATP-citrate lyase inhibitor, but the supplied evidence does not independently validate both mechanisms or establish translational applications. This overview separates catalog claims from the supplied peer-reviewed synthesis paper, evaluates conceptual research uses, and defines the main evidence and applicability limits.

• Candida krusei Apoptosis in Bovine Mammary Cells

  2026-10-09

  A 2023 study found that the yeast and hypha phases of Candida krusei induce apoptosis in bovine mammary epithelial cells through different dominant pathways. Its phase-resolved design links yeast-associated injury mainly to mitochondrial signaling, whereas hypha-associated apoptosis is more closely associated with death ligand/receptor signaling and shared TLR–MAPK responses.

• Luminescent ATP Cell Viability Assay Kit I for Ferroptosis

  2026-10-08

  The Luminescent ATP Cell Viability Assay Kit I provides a rapid, sensitive ATP-based endpoint for studying ferroptosis and cytotoxic responses. This article explains how luciferase luminescence detection can strengthen mechanistic interpretation without treating viability loss as proof of a specific death pathway.

• How Dual-Action Inhibitors Tune p38α Dephosphorylation

  2026-10-08

  A 2024 bioRxiv preprint reports that selected kinase inhibitors can do more than block p38α catalytic activity: they can also favor an activation-loop conformation that makes the regulatory phosphothreonine more accessible to WIP1 phosphatase. The structural and biochemical findings introduce a mechanism for coupling kinase inhibition with accelerated dephosphorylation, while remaining an early, primarily reconstituted-system result rather than a clinical or cellular efficacy demonstration.

• Cross-Kingdom Promoters Need Better Readouts

  2026-10-07

  Synthetic promoters that operate across bacteria and yeast could make genetic systems more portable, but portability is only useful when expression can be measured consistently. This thought-leadership article examines the mechanistic rationale, reported validation, translational boundaries, and strategic role of β-galactosidase reporter assays in evaluating cross-kingdom expression systems.

• Bufalin: From Cardiotonic Steroid to Translational Probe

  2026-10-07

  Bufalin is emerging as a mechanistically rich oncology research compound. New pre-proof evidence connects it with CENPA-associated glycolysis, PI3K/AKT signaling, and migration in hepatocellular carcinoma, while broader research positions the cardiotonic steroid as an apoptosis inducer and possible molecular-glue degrader. This article assesses the evidence, translational opportunities, limitations, and strategic questions that should guide future investigation.

• VX-765 and the Blood–Brain Barrier: 5 Questions

  2026-10-06

  A source-grounded overview of what VX-765 reveals about caspase-1 signaling and blood–brain barrier injury, including evidence strength, interpretation, scope, and key limitations.

• Methylprednisolone in Inflammation and Bone Research

  2026-10-05

  Methylprednisolone is a synthetic glucocorticoid receptor agonist studied across inflammatory and skeletal disease models. This overview compares supplier-described anti-inflammatory mechanisms with findings from a 2024 rat study of glucocorticoid-induced osteonecrosis of the femoral head, while emphasizing evidence strength, translational limits, and unresolved questions.

• YM 58483 (BTP2): SOCE, Fibrosis, Translation

  2026-10-05

  YM 58483 (BTP2) offers a pathway-level lens on sustained calcium entry across immune activation and radiation-associated salivary gland fibrosis. This thought-leadership analysis connects SOCE biology with the ORAI2/JNK/NFAT1/TGF-β1 axis while separating reported preclinical findings from translational hypotheses and evidence limitations.

• Toremifene in Prostate Cancer Research: Evidence

  2026-10-04

  Toremifene is a selective estrogen-receptor modulator studied in hormone-related cancer models, while recent prostate cancer research has identified a distinct TSPAN18–STIM1 calcium-signaling mechanism associated with bone metastasis. This overview separates supplier-reported Toremifene activity from peer-reviewed findings, evaluates conceptual links between estrogen receptor signaling and metastatic biology, and outlines evidence limitations. Current evidence does not establish that Toremifene directly inhibits, activates, or otherwise regulates the TSPAN18–STIM1 axis.

8665 records 1/578 page Next 12345 下5页 Last page